Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application
11:17am, Friday, 11'th Jul 2025
Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the co
Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock
09:03am, Friday, 11'th Jul 2025
Capricor Therapeutics Inc. CAPR stock is trading lower on Friday.
Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
08:20am, Friday, 11'th Jul 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 300 points on Friday.
US FDA declines to approve Capricor's muscle disorder therapy
06:36am, Friday, 11'th Jul 2025
Capricor Therapeutics said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy for a type of muscle disorder.
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
06:30am, Friday, 11'th Jul 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
03:58pm, Monday, 07'th Jul 2025
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors ar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Thursday, 03'rd Jul 2025
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors ar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
05:10pm, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors ar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?
10:01am, Wednesday, 25'th Jun 2025
Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy
02:51pm, Tuesday, 24'th Jun 2025
Capricor Therapeutics Inc CAPR on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company's lead cell therapy candidate for the treatment of
No Ad Comm 'not necessarily positive' for Capricor, says Roth Capital
12:11pm, Tuesday, 24'th Jun 2025
31 Aug 17 Oct
US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy
09:16am, Tuesday, 24'th Jun 2025
Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration will not convene its panel of outside experts before deciding on the company's cell therapy for a heart condition associated
Why Is Capricor Therapeutics Stock Trading Lower On Monday?
12:46pm, Monday, 23'rd Jun 2025
Capricor Therapeutics, Inc. CAPR stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per data from Benzinga Pro.
